Regulatory Routine +

Zentek Accepting Canadian Commercial Orders for ZenGUARD(TM) Enhanced Air Filters Following Health Canada Regulatory Classification

Regulatory Clearance Unlocks ZenGUARD Sales, But Nasdaq Compliance Looms

By The Northwire Desk — AI Analysis May 06, 2026 · 12:01 ZEN · 0.69 Zentek Ltd.

Executive Summary

Zentek Ltd. announced on May 6, 2026, that Health Canada's Pesticides Regulatory Directorate (PRD) has classified ZenGUARD™ Enhanced Air Filters as not subject to regulation under the Pest Control Products Act.
The exemption is based on a mechanical mode of action, resolving a regulatory uncertainty previously disclosed in February 2026 where the product was under evaluation as a "pest control product."
Following this classification, Zentek is officially accepting commercial orders in Canada across four pathways: Direct Purchase Orders, Federal Procurement (Innovative Solutions Canada), Licensing with HVAC supply chain participants, and Coated Filter Media sales.
The product maintains MERV 9 filtration validated under ASHRAE 52.2 with pressure drop equivalent to uncoated filters.
Intellectual Property is protected by an issued Canadian patent extending to 2041.

Material Impact

Regulatory Risk Removal: This news removes a specific commercialization blocker identified in the February 17, 2026 strategic update. Previously, Health Canada's classification as a "pest control product" could have delayed or complicated sales; this exemption accelerates revenue potential in the Canadian market.
Commercial Execution: While accepting orders is positive, it does not guarantee immediate volume or cash flow. The company must now convert these pathways into actual invoices to impact financials materially.
Contextual Performance: This follows a series of operational milestones (Albany Graphite PEA progress, Triera CRO launch, Litigation victory) but lacks the capital injection or strategic investment required for a "Material - Game Changer" rating.
Market Reaction Risk: The stock price has declined significantly from $2.38 highs to ~$0.69 lows over the past year. While this news is positive, it may be viewed as expected progress by the market given the February 2026 disclosure of ongoing regulatory engagement.
Nasdaq Compliance Shadow: The most critical context is the Nasdaq minimum bid price requirement ($1.00) with a deadline of August 24, 2026. Current trading levels (~$0.69) are well below this threshold. This news does not directly address the share price compliance issue, which remains a material risk to listing status.

ZEN · Price

Company Overview

Company: Zentek Ltd. is a diversified technology company focused on critical minerals (graphite), advanced materials (air filtration), and biotechnology (aptamers).
Flagship Project 1 - Albany Graphite: Located in Ontario, Canada. Aims to produce ultra-high-purity (5N+) nuclear-grade graphite using an electrothermal fluidized bed reactor (FBR) process without chlorine. Currently advancing toward a Preliminary Economic Assessment (PEA) targeted for Summer 2026.
Flagship Project 2 - ZenGUARD: Graphene-enhanced air filters designed to remove infectious aerosols while maintaining energy efficiency. Recently cleared by Health Canada for commercial sale in Canada.
Flagship Project 3 - Triera Biosciences: Subsidiary focused on aptamer-based therapeutics and diagnostics (e.g., influenza, H5N1). Generating revenue through CRO services.

More from Zentek Ltd.